甲状腺癌诊断市场份额，规模，趋势，行业分析报告，按类型（乳头状癌，滤泡癌）;通过技术（血液测试，成像，活检）;通过终用（医院实验室，癌症诊断中心，研究机构）;按地区;分部预测，2021 - 2028

报告摘要

2020年全球甲状腺癌诊断市场的价值为250亿美元，预计预测期内的CAGR增长率为5.7％。甲状腺癌的普遍性越来越关注早期诊断，加上全球人口老龄化人口是负责市场增长的突出因素。

甲状腺癌是一种常见的恶性内分泌腺。乳头状和卵泡癌占甲状腺癌的90％。据估计，甲状腺癌的患病率为4.5％的女性和2％的男性。在20-34岁之间的白种人女性中，这种情况更为普遍。此外，政府倡议上市和对早期诊断的资金增加，也有利于有关诊断市场增长。

了解有关此报告的更多信息：request for sample pages

Industry Dynamics

Growth Drivers
大多数协会和学术机构都参与了研发，以开发新产品和服务，以更好的治疗，诊断和预防甲状腺癌。必威开户注册例如，美国甲状腺组织和甲状腺癌幸存者协会参与了更深入了解分子机制的活动，鉴定有针对性诊断和治疗方法的关键基因。2018年，国家癌症研究所（NCI），我的儿科和成人稀有肿瘤网络已经为患有髓质甲状腺癌的人建立了罕见的肿瘤设施，他没有接受标准治疗。

研究ers used these tissue samples to understand the genetics behind it, to create an effective treatment manual. Moreover, in the same year, FDA approved the combination therapy in the market involving two drugs dabrafenib mesylate and trametinib for the treatment of anaplastic thyroid cancers, having a mutation in the BRAF gene. It is being estimated that more than a quarter of anaplastic thyroid cancers have this kind of mutation.

甲状腺癌诊断市场报告范围

该市场主要是在类型，技术，最终用途和地区进行分段。

By Type	By Technique	通过最终使用	按地区
乳头状癌 毛囊癌 Others	Blood Test 成像 活检 Others	Hospital Laboratories 癌症诊断中心 研究机构 Others	北美（美国，加拿大） 欧洲（法国，德国，英国，意大利，西班牙，荷兰，奥地利） Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea) 拉丁美洲（巴西，墨西哥，阿根廷） 中东和非洲（沙特阿拉伯，阿联酋，以色列，南非）

了解有关此报告的更多信息：request for sample pages

Insight by Type

基于该类，全球甲状腺癌诊断市场分为乳头状，滤泡癌等。2020年，乳头状癌细分占最大的市场收入份额。相关病症在所有癌症中具有最高的治愈率，5年生存率近98％。

Follicular carcinomas are expected to witness lucrative market growth over the assessment period. These are the most common form, including anaplastic, medullary, Hurthle carcinomas. Follicular carcinomas have worst prognosis rate as it metastasizes to the several lymph nodes at a very early stage, thereby requiring complicated surgery.

Insight by Technique

基于该技术，全球甲状腺癌诊断市场分叉进入血液测试，成像，活检等。在2020年，成像分部占最大份额。如此高的份额是由于成像测试是疾病诊断的主要要求。甲状腺超声评估结构异常，而血液试验测量甲状腺素，T3和T4水平以检查功能差异。

Moreover, the diagnostics market landscape in thyroid cancer is fueled by genetic prognosis and molecular tests. Neck ultrasounds are the most common tools for cancer diagnosis. Other imaging tests include chest X-ray, PET scan, and bone scans to identify metastasis. Moreover, concerning diagnostics technology investments and high procedure cost also contributing to the segment’s growth.

Insight by End-Use

Based on the end-use, the global market is bifurcated into hospital laboratories, cancer diagnostics centers, research institutes, and others. In 2020, the hospital labs segment accounted for the largest share. Concerned diagnostics market growth is attributed to a rising patient suffering from thyroid cancers, patient awareness regarding early diagnosis, and rising investments in healthcare infrastructure.

However, the research institutes market segment is projected to witness the highest growth rate over the assessment period. This is due to rising research funding towards cancer research, for instance, American Thyroid Association (ATA) has funded over 105 research grants, valuing around USD 2.8 million.

Geographic Overview

地理上，全球诊断市场分叉进入北美，亚太地区，欧洲，拉丁美洲和中东和非洲。北美是欧洲和亚太地区之后最大的收入贡献者。2020年，北美地区占全球市场的42％以上。

Regional factors responsible for the diagnostics market growth include strong industry-academia collaboration, the presence of suitable research infrastructure, the presence of key companies, and the high disposable income of people who can afford such high-cost drugs.

亚太地区预计将在评估期间见证有关诊断市场的最高增长。甲状腺癌高患病率，改善印度和中国的医疗保健基础设施，患者对其不良影响的认识。betway体育亚洲版入口

竞争洞察力

The prominent players operating in the market are Abbott, Roche Ltd, Thermo Fisher Scientific, Siemens Healthcare, Bio-Rad Laboratories, General Electric, Koninklijke Philips, Toshiba Corporation, Agilent Technologies, and Illumina, Inc.